Risk Reward Update for 3SBio (1530.HK)
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
Morgan Stanley updated its risk-reward analysis for 3SBio (1530.HK), lowering the price target from HK$38 to HK$34 while maintaining an Overweight rating. The current share price of HK$22.96 implies approximately 48% upside potential to the new target.
The revision reflects the incorporation of 2025 actual results and adjustments to TPIAO sales expectations and milestone payments, exacerbated by US dollar depreciation against the renminbi. Consequently, revenue forecasts for 2026–2028 were trimmed by 5%, 7%, and 6%, respectively, with corresponding EPS reductions of 8.3%, 14.5%, and 12.4%. Gross margin estimates declined while operating expense ratios were recalibrated. The updated DCF valuation uses a WACC of 10.0%, a 2% terminal growth rate, and an RMB/HKD exchange rate assumption of 1.14.
The strategic collaboration with Pfizer on SSGJ-707 remains the primary catalyst, validating 3SBio's mammalian cell biopharmaceutical platform and potentially driving sustainable long-term financial growth. Although certain legacy products face competitive pressure from next-generation therapies, these headwinds should be offset by business development payments and pipeline advancements. Global optionality includes PD-1 bispecific antibodies and a BDCA2 antibody, currently excluded from valuation.
Bull and bear case targets are HK$45 and HK$15, respectively. Key downside risks include slower-than-expected SSGJ-707 global trial progression, intensifying pricing pressure on EPO and TPIAO, and potential pipeline setbacks.